文献速递免疫规划妇幼与学校卫生

母体抗体对活病毒与重组轮状病毒疫苗免疫原性的不同影响

The distinct impact of maternal antibodies on the immunogenicity of live and recombinant rotavirus vaccines.
PubMed 文献 · Vaccine · 2019-06-07

在低收入国家轮状病毒相关发病率和死亡率高,母体抗体滴度高可能是轮状病毒疫苗效力降低的因素之一。本研究在小鼠模型中评估母体抗体对活病毒疫苗和重组VP4*疫苗的影响,发现母体抗体抑制活疫苗的中和抗体和IgA应答(尤其经乳抗体),但增强重组VP4*疫苗的中和抗体应答。

要点

  • 母体抗体抑制活轮状病毒疫苗的中和抗体和IgA应答,尤其经乳抗体。
  • 母体抗体增强重组VP4*疫苗的中和抗体应答。
  • VP4*与轮状病毒免疫血清体外孵育也可增强免疫应答。

核心结论

  • 母体抗体对活轮状病毒疫苗和重组VP4*疫苗免疫原性的影响不同:抑制活疫苗应答,增强重组疫苗应答。

研究设计与样本

  • 小鼠模型研究:母鼠产后7天经口感染鼠轮状病毒以模拟婴儿自然感染,通过半窝交换区分经胎盘和经乳获得的母体抗体。

主要发现

  • 活轮状病毒免疫后,中和抗体和IgA抗体应答均被母体抗体抑制,尤其是经乳抗体。
  • 重组VP4*免疫后,中和抗体应答被母体抗体增强。
  • VP4*与轮状病毒免疫血清体外孵育也可增强免疫应答。

临床怎么用

  • 为开发非复制型疫苗以解决中低收入国家活减毒疫苗问题提供依据。

局限性

  • 研究为小鼠模型,结果向人类婴儿的外推需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A high titre of maternal antibodies is one of the possible factors associated with decreased rotavirus vaccine efficacy in low-income countries where rotavirus-associated morbidity and mortality are high. Although some studies show a negative correlation between maternal antibody levels and seroconversion after vaccination, withholding breastfeeding does not improve rotavirus vaccine efficacy. Different types of recombined vaccines were developed as an alternative to produce higher protection in developing areas. In previous studies, we found that recombinantly expressed, truncated VP4* can stimulate high titres of neutralizing antibodies and can confer protection against rotavirus infections and rotavirus-induced diarrhoea. In this study, the impact of maternal antibodies on live and recombinant rotavirus vaccines (VP4*) was evaluated in a mouse model. Dams were infected orally with murine rotavirus 7 days after delivery to mimic a natural rotavirus infection in infants and to evaluate the separate effects of trans-placentally acquired and milk-acquired maternal antibodies, pups were half exchanged. After immunization with live rotavirus, both the neutralizing antibody and IgA antibody responses were inhibited by maternal antibodies, especially by milk antibodies; however, the neutralizing antibody responses after immunization with recombinant VP4* were enhanced. In addition, the in vitro incubation of VP4* with immune sera of rotavirus could also enhance the immune responses could also enhance the immune responses. Our finding provides a basis for the development of non-replicating vaccines to address the problem of live attenuated vaccines in low- and middle-income countries.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yang H, Luo G, Zeng Y, et al. The distinct impact of maternal antibodies on the immunogenicity of live and recombinant rotavirus vaccines. Vaccine. 2019. PMID: 31182323. doi:10.1016/j.vaccine.2019.05.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。